Prognostic significance of 18F-FDG PET at diagnosis in patients with soft tissue sarcoma and bone sarcoma; systematic review and meta-analysis

2016 ◽  
Vol 58 ◽  
pp. 104-111 ◽  
Author(s):  
Tadahiko Kubo ◽  
Taisuke Furuta ◽  
Muhammad P. Johan ◽  
Mitsuo Ochi
Keyword(s):  
Systematic Review ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Fdg Pet ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Bone Sarcoma ◽  
18F Fdg

scholarly journals Assessing the role of 18F-FDG PET and 18F-FDG PET/CT in the diagnosis of soft tissue musculoskeletal malignancies: a systematic review and meta-analysis

2015 ◽  
Vol 43 (5) ◽  
pp. 860-870 ◽  
Author(s):  
Elba C. Etchebehere ◽  
Brian P. Hobbs ◽  
Denái R. Milton ◽  
Osama Malawi ◽  
Shreyaskumar Patel ◽  
...  
Keyword(s):  
Systematic Review ◽  
Soft Tissue ◽  
Fdg Pet ◽  
Meta Analysis ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals Volume of interest delineation techniques for 18F-FDG PET-CT scans during neoadjuvant extremity soft tissue sarcoma treatment in adults: a feasibility study

2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Marc G. Stevenson ◽  
Lukas B. Been ◽  
Harald J. Hoekstra ◽  
Albert J. H. Suurmeijer ◽  
Ronald Boellaard ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Fdg Pet ◽  
Ct Scans ◽  
Volume Of Interest ◽  
Extremity Soft Tissue Sarcoma ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Sarcoma Treatment

scholarly journals Neoadjuvant Pazopanib Treatment in High-Risk Soft Tissue Sarcoma: A Quantitative Dynamic 18F-FDG PET/CT Study of the German Interdisciplinary Sarcoma Group

Cancers ◽  
2019 ◽  
Vol 11 (6) ◽  
pp. 790 ◽  
Author(s):  
Christos Sachpekidis ◽  
Ioannis Karampinis ◽  
Jens Jakob ◽  
Bernd Kasper ◽  
Kai Nowak ◽  
...  
Keyword(s):  
High Risk ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Kinetic Analysis ◽  
Quantitative Evaluation ◽  
Fdg Pet ◽  
Standardized Uptake Value ◽  
Pet Ct ◽  
18F Fdg ◽  
Regression Grade

The outcome of high-risk soft tissue sarcoma (STS) is poor with radical surgery being the only potentially curative modality. Pazopanib is a multikinase inhibitor approved for the treatment of metastatic STS. Herein, in terms of the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS) trial, we evaluate the potential role of kinetic analysis of fludeoxyglucose F-18 (18F-FDG) data derived from the application of dynamic positron emission tomography/computed tomography (PET/CT) in response assessment to pazopanib of STS patients scheduled for surgical resection. Sixteen STS patients treated with pazopanib as neoadjuvant therapy before surgery were enrolled in the analysis. All patients underwent dynamic PET/CT prior to and after pazopanib treatment. Data analysis consisted of visual (qualitative) analysis of the PET/CT scans, semi-quantitative evaluation based on standardized uptake value (SUV) calculations, and quantitative analysis of the dynamic 18F-FDG PET data, based on two-tissue compartment modeling. Resection specimens were histopathologically assessed and the percentage of regression grade was recorded in 14/16 patients. Time to tumor relapse/progression was also calculated. In the follow-up, 12/16 patients (75%) were alive without relapse, while four patients (25%) relapsed, among them one patient died. Median histopathological regression was 20% (mean 26%, range 5–70%). The studied population was dichotomized using a histopathological regression grade of 20% as cut-off. Based on this threshold, 10/14 patients (71%) showed partial remission (PR), while stable disease (SD) was seen in the rest 4 evaluable patients (29%). Semi-quantitative evaluation showed no statistically significant change in the widely used PET parameters, SUVaverage and SUVmax. On the other hand, 18F-FDG kinetic analysis revealed a significant decrease in the perfusion-related parameter K1, which reflects the carrier-mediated transport of 18F-FDG from plasma to tumor. This decrease can be considered as a marker in response to pazopanib in STS and could be due to the anti-angiogenic effect of the therapeutic agent.

scholarly journals Correction: Diagnostic role of 18F-FDG PET/MRI in patients with gynecological malignancies of the pelvis: A systematic review and meta-analysis

PLoS ONE ◽  
2018 ◽  
Vol 13 (8) ◽  
pp. e0202314 ◽  
Author(s):  
Ji Nie ◽  
Jing Zhang ◽  
Jinsheng Gao ◽  
Linghong Guo ◽  
Hui Zhou ◽  
...  
Keyword(s):  
Systematic Review ◽  
Fdg Pet ◽  
Meta Analysis ◽  
Gynecological Malignancies ◽  
Diagnostic Role ◽  
18F Fdg

scholarly journals NI-04 WHICH RADIOLOGICAL IMAGING IS BEST TO DISCRIMINATE RADIATION NECROSIS FROM TUMOR PROGRESSION? - SUBANALYSIS OF SYSTEMATIC REVIEW FOR RADIOLOGICAL DIAGNOSIS OF RADIATION NECROSIS

2019 ◽  
Vol 1 (Supplement_2) ◽  
pp. ii26-ii26
Author(s):  
Motomasa Furuse ◽  
Naosuke Nonoguchi ◽  
Kei Yamada ◽  
Tohru Shiga ◽  
Jean-Damien Combes ◽  
...  
Keyword(s):  
Systematic Review ◽  
Tumor Progression ◽  
Fdg Pet ◽  
Radiation Necrosis ◽  
Meta Analysis ◽  
Radiological Imaging ◽  
Imaging Studies ◽  
Enhanced Mri ◽  
Multiple Imaging ◽  
18F Fdg

Abstract BACKGROUND It is challenging to discriminate radiation necrosis from tumor progression, especially in malignant glioma. Therefore many radiological imaging studies have been reported. In this study, we performed a systematic review of radiological diagnosis for radiation necrosis and analyzed the best radiological imaging for malignant glioma. METHODS We divided diagnostic approaches into two categories as follows-CT and MRI (conventional radiological imaging studies), and SPECT and PET (nuclear medicine studies). Our librarians conducted a comprehensive systematic search on Pub Med, Cochrane Library, and the Japan Medical Abstract Society up to March 2015. The searching keywords included radiation necrosis, recurrence, imaging modalities such as MRI, diagnosis, and differential. In a meta-analysis, diagnostic odds ratio (DOR) was calculated. A subanalysis was performed, dividing into tumor types, gliomas and metastatic brain tumors. RESULTS Of 188 and 239 records extracted from the database, 20 and 26 studies were included in the meta-analysis after exclusion of case reports and studies with incompatible content and insufficient information. Gd-enhanced MRI exhibited the lowest sensitivity (63%) and DOR (2.2). On the other hand, combined multiple imaging studies including MRS and perfusion image displayed the highest sensitivity (96%) and DOR (5.9). In the subanalysis for glioma, Gd-enhanced MRI and 18F-FDG-PET revealed low DORs (1.7 and 2.3). Conversely, 18F-FET-PET and combined multiple imaging studies showed high DORs (6.8 and 5.9). CONCLUSIONS Gd-enhanced MRI had low diagnostic ability for differentiation of radiation necrosis. In glioma patients, 18F-FDG-PET was not useful to discriminate radiation necrosis from tumor progression. Combined multiparametric imaging including lesional metabolism and blood flow could enhance diagnostic accuracy and be useful to differentiate radiation necrosis from tumor progression even in glioma patients.

The role of 18F-FDG PET/CT in soft tissue sarcoma

2019 ◽  
Vol 40 (6) ◽  
pp. 626-631 ◽  
Author(s):  
Andrea Sambri ◽  
Giuseppe Bianchi ◽  
Alessandra Longhi ◽  
Alberto Righi ◽  
Davide Maria Donati ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Fdg Pet ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Risk stratification and prognosis determination using 18F-FDG PET imaging in endometrial cancer patients: A systematic review and meta-analysis

2014 ◽  
Vol 132 (3) ◽  
pp. 669-676 ◽  
Author(s):  
Haleh Ghooshkhanei ◽  
Giorgio Treglia ◽  
Golnaz Sabouri ◽  
Rozita Davoodi ◽  
Ramin Sadeghi
Keyword(s):  
Systematic Review ◽  
Endometrial Cancer ◽  
Risk Stratification ◽  
Cancer Patients ◽  
Pet Imaging ◽  
Fdg Pet ◽  
Meta Analysis ◽  
18F Fdg
Sign in / Sign up

Export Citation Format

Share Document